Organization
Shanghai Jiaolian Drug Research and Development
7 clinical trials
Clinical trial
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles and Preliminary Efficacy of Subcutaneous Injection of Recombinant Humanized Anti-CD20 Monoclonal Antibody in the Treatment of Primary Membranous NephropathyStatus: Recruiting, Estimated PCD: 2024-03-31
Clinical trial
A Phase II/III Study to Evaluate the Efficacy and Safety of B013 in Combination With Nab-Paclitaxel in First-line Treatment for Patients With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast CancerStatus: Recruiting, Estimated PCD: 2024-03-01
Clinical trial
A Multicenter, Randomized, Double-blind, Parallel-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of B013 Combined With Paclitaxel in the Treatment of Platinum-resistant Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer.Status: Not yet recruiting, Estimated PCD: 2026-12-31
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II/III Clinical Study to Evaluate the Efficacy and Safety of B007 in Subjects With Generalized Myasthenia GravisStatus: Not yet recruiting, Estimated PCD: 2026-06-30
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II/III Clinical Study to Evaluate the Efficacy and Safety of B001 Injection in Aquaporin-4 Antibody Positive Patients With Neuromyelitis Optica Spectrum DisorderStatus: Not yet recruiting, Estimated PCD: 2027-10-31
Clinical trial
A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of B007 in Subjects With Pemphigus.Status: Not yet recruiting, Estimated PCD: 2026-12-31
Clinical trial
A Multicenter, Randomized, Controlled, Open Phase II/III Clinical Study to Evaluate the Efficacy and Safety of B007 Versus Cyclosporine in the Treatment of Primary Membranous Nephropathy.Status: Not yet recruiting, Estimated PCD: 2026-12-31